Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 2 (February)

1. Laparoscopic-assisted vs. open colectomy for colon cancer: a prospective randomized trial.
   J Laparoendosc Adv Surg Tech A, 14(6): 329-34. [Abstract] [Full-text]
2. Colon epithelial cell differentiation is inhibited by constitutive c-myb expression or mutant APC plus activated RAS.
   DNA Cell Biol, 24(1): 21-9. [Abstract] [Full-text]
3. Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer.
   Pacing Clin Electrophysiol, 28: S120-3. [Abstract] [Full-text]
4. Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis.
   J Gastroenterol Hepatol, 20(2): 173-81. [Abstract] [Full-text]
5. Identification and phenotypic characterization of a subpopulation of T84 human colon cancer cells, after selection on activated endothelial cells.
   J Cell Physiol, 203(1): 261-72. [Abstract] [Full-text]
6. The double-barreled wet ileostomy: an alternative method for simultaneous urinary and intestinal diversion without intestinal anastomosis after total colectomy and pelvic exenteration.
   Int J Colorectal Dis, 20(2): 190-3. [Abstract] [Full-text]
7. Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
   Int J Colorectal Dis, 20(2): 161-4. [Abstract] [Full-text]
8. Lymph node evaluation in colorectal cancer patients: a population-based study.
   J Natl Cancer Inst, 97(3): 219-25. [Abstract] [Full-text]
9. Requirement of phospholipase D1 activity in H-RasV12-induced transformation.
   Proc Natl Acad Sci U S A, 102(5): 1638-42. [Abstract] [Full-text]
10. Foxl1 is a mesenchymal Modifier of Min in carcinogenesis of stomach and colon.
    Genes Dev, 19(3): 311-5. [Abstract] [Full-text]
11. Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study.
    Int J Colorectal Dis, 20(2): 147-54. [Abstract] [Full-text]
12. Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use?
    Int J Colorectal Dis, 20(2): 137-46. [Abstract] [Full-text]
13. Prospective, randomized trial examining the role of gentamycin-containing collagen sponge in the reduction of postoperative morbidity in rectal cancer patients: early results and surprising outcome at 3-year follow-up.
    Int J Colorectal Dis, 20(2): 114-20. [Abstract] [Full-text]
14. Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor.
    Int J Colorectal Dis, 20(2): 103-13. [Abstract] [Full-text]
15. Metachronous colorectal cancer: necessity of post-operative colonoscopic surveillance.
    Int J Colorectal Dis, 20(2): 121-5. [Abstract] [Full-text]
16. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer.
    Int J Colorectal Dis, 20(2): 94-102. [Abstract] [Full-text]
17. Redefining the subcellular location and transport of APC: new insights using a panel of antibodies.
    EMBO Rep, 6(2): 184-90. [Abstract] [Full-text]
18. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.
    J Clin Invest, 115(2): 339-47. [Abstract] [Full-text]
19. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin.
    Oncogene, 24(6): 1021-31. [Abstract] [Full-text]
20. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.
    Oncogene, 24(6): 1098-103. [Abstract] [Full-text]
21. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
    Blood, 105(4): 1734-41. [Abstract] [Full-text]
22. Dual-channel photobleaching FRET microscopy for improved resolution of protein association states in living cells.
    Eur Biophys J, 34(1): 82-90. [Abstract] [Full-text]
23. The use of endoscopic ultrasound-guided fine-needle aspiration for investigation of submucosal and extrinsic masses of the colon and rectum.
    Endoscopy, 37(2): 154-60. [Abstract] [Full-text]
24. Dietary patterns and colorectal adenomas in Japanese men: the Self-Defense Forces Health Study.
    Am J Epidemiol, 161(4): 338-45. [Abstract] [Full-text]
25. Converging patterns of colorectal cancer mortality in Europe.
    Eur J Cancer, 41(3): 430-7. [Abstract] [Full-text]
26. Colorectal cancer risk after colonoscopic polypectomy: a population-based study and literature search.
    Eur J Cancer, 41(3): 416-22. [Abstract] [Full-text]
27. Iron deficiency anemia in patients without gastrointestinal symptoms--a prospective study.
    Fam Pract, 22(1): 58-61. [Abstract] [Full-text]
28. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
    Cancer Immunol Immunother, 54(4): 315-27. [Abstract] [Full-text]
29. Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.
    Mol Carcinog, 42(2): 109-20. [Abstract] [Full-text]
30. Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
    Semin Oncol, 31(6): 17-21. [Abstract] [Full-text]
31. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Semin Oncol, 31(6): 10-6. [Abstract] [Full-text]
32. Angiogenesis and its role in colorectal tumor and metastasis formation.
    Semin Oncol, 31(6): 3-9. [Abstract] [Full-text]
33. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials.
    J Gastrointest Surg, 9(2): 198-206. [Abstract] [Full-text]
34. Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience.
    J Gastrointest Surg, 9(2): 178-86. [Abstract] [Full-text]
35. Autologous fashioned graft for aneurysm repair in a contaminated field.
    Eur J Vasc Endovasc Surg, 29(3): 247-9. [Abstract] [Full-text]
36. Mitochondrial microsatellite instability in colorectal carcinomas--frequency and association with nuclear microsatellite instability.
    Cancer Lett, 219(1): 97-103. [Abstract] [Full-text]
37. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
    Cancer Lett, 219(1): 41-8. [Abstract] [Full-text]
38. Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production.
    Br J Pharmacol, 144(3): 338-48. [Abstract] [Full-text]
39. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
    J Biol Chem, 280(5): 3217-23. [Abstract] [Full-text]
40. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Z Gastroenterol, 43(2): 155-61. [Abstract] [Full-text]
41. Population-based registration of unselected colorectal cancer patients: five-year survival in the region of Bonn/Rhine-Sieg, Germany.
    Z Gastroenterol, 43(2): 149-54. [Abstract] [Full-text]
42. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
    Eur J Surg Oncol, 31(2): 147-52. [Abstract] [Full-text]
43. Neoadjuvant chemotherapy does not increase postoperative complication rate after resection of colorectal liver metastases.
    Eur J Surg Oncol, 31(2): 141-6. [Abstract] [Full-text]
44. Squamous cell carcinoma of the rectum: a case report and review of the literature.
    Eur J Cancer Care (Engl), 14(1): 70-4. [Abstract] [Full-text]
45. Development and evaluation of an information booklet/decision-making guide for patients with colorectal cancer considering therapy in addition to surgery.
    Eur J Cancer Care (Engl), 14(1): 16-27. [Abstract] [Full-text]
46. Heparanase expression correlates with malignant potential in human colon cancer.
    J Cancer Res Clin Oncol, 131(4): 229-37. [Abstract] [Full-text]
47. A matched, case-control study of the association between Schistosoma japonicum and liver and colon cancers, in rural China.
    Ann Trop Med Parasitol, 99(1): 47-52. [Abstract] [Full-text]
48. Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis.
    Br J Cancer, 92(3): 430-3. [Abstract] [Full-text]
49. P53 abnormalities and outcomes in colorectal cancer: a systematic review.
    Br J Cancer, 92(3): 434-44. [Abstract] [Full-text]
50. hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients.
    Br J Cancer, 92(2): 396-404. [Abstract] [Full-text]
51. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
    Br J Cancer, 92(2): 259-64. [Abstract] [Full-text]
52. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.
    Br J Cancer, 92(2): 350-8. [Abstract] [Full-text]
53. Progressive loss of endothelial P-selectin expression with increasing malignancy in colorectal cancer.
    Lab Invest, 85(2): 248-56. [Abstract] [Full-text]
54. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
    Br J Cancer, 92(1): 24-9. [Abstract] [Full-text]
55. Peri-operative filtration of disseminated cytokeratin positive cells in patients with colorectal liver metastasis.
    Langenbecks Arch Surg, 390(1): 15-20. [Abstract] [Full-text]
56. Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal cancers, disclosed by area-specific four-point tissue microarrays.
    Lab Invest, 85(2): 257-66. [Abstract] [Full-text]
57. Signet ring cell carcinoma of the colorectum: correlations between microsatellite instability, clinicopathologic features and survival.
    Mod Pathol, 18(2): 244-9. [Abstract] [Full-text]
58. Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
    Mod Pathol, 18(2): 212-20. [Abstract] [Full-text]
59. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
    J Clin Oncol, 23(5): 973-81. [Abstract] [Full-text]
60. Progressive methylation during the serrated neoplasia pathway of the colorectum.
    Mod Pathol, 18(2): 170-8. [Abstract] [Full-text]
61. Measurements of T1 and T2 relaxation times of colon cancer metastases in rat liver at 7 T.
    MAGMA, 17(3): 281-7. [Abstract] [Full-text]
62. Statistical methods of translating microarray data into clinically relevant diagnostic information in colorectal cancer.
    Bioinformatics, 21(4): 517-28. [Abstract] [Full-text]
63. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
    Jpn J Clin Oncol, 35(2): 88-9. [Abstract] [Full-text]
64. Induced oxidative stress and decreased expression of inducible heat shock protein 70 (ihsp 70) in patients with colorectal adenocarcinomas.
    Jpn J Clin Oncol, 35(2): 74-8. [Abstract] [Full-text]
65. Solar radiation, vitamin D and survival rate of colon cancer in Norway.
    J Photochem Photobiol B, 78(3): 189-93. [Abstract] [Full-text]
66. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(3): 665-77. [Abstract] [Full-text]
67. Citri Reticulatae Viride Pericarpium extract induced apoptosis in SNU-C4, human colon cancer cells.
    J Ethnopharmacol, 97(2): 231-5. [Abstract] [Full-text]
68. Overexpression of DARPP-32 in colorectal adenocarcinoma.
    Int J Clin Pract, 59(1): 58-61. [Abstract] [Full-text]
69. Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon.
    Hum Pathol, 36(1): 101-11. [Abstract] [Full-text]
70. Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics.
    Hum Pathol, 36(1): 66-73. [Abstract] [Full-text]
71. Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells.
    Biochem Pharmacol, 69(5): 801-9. [Abstract] [Full-text]
72. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
    Am J Prev Med, 28(2): 208-14. [Abstract] [Full-text]
73. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.
    Aliment Pharmacol Ther, 21(4): 321-39. [Abstract] [Full-text]
74. Receipt of colorectal testing prior to colorectal carcinoma diagnosis.
    Cancer, 103(4): 696-701. [Abstract] [Full-text]
75. Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus.
    Int J Cancer, 114(4): 659-64. [Abstract] [Full-text]
76. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population.
    Int J Cancer, 114(3): 433-5. [Abstract] [Full-text]
77. Analysis of allelic imbalances at multiple cancer-related chromosomal loci and microsatellite instability within the same tumor using a single tumor gland from colorectal carcinomas.
    Int J Cancer, 114(3): 337-45. [Abstract] [Full-text]
78. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy.
    Int J Cancer, 114(3): 490-7. [Abstract] [Full-text]
79. Quality of life and diet intervention in individuals at risk for recurrence of colorectal adenomas.
    Psychooncology, 14(2): 85-93. [Abstract] [Full-text]
80. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer.
    J Natl Cancer Inst, 97(4): 282-92. [Abstract] [Full-text]
81. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector?
    J Natl Cancer Inst, 97(4): 257-64. [Abstract] [Full-text]
82. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.
    JAMA, 293(7): 799-809. [Abstract] [Full-text]
83. Overexpression of RGC-32 in colon cancer and other tumors.
    Exp Mol Pathol, 78(2): 116-22. [Abstract] [Full-text]
84. Cytotoxic activities of chitosan nanoparticles and copper-loaded nanoparticles.
    Bioorg Med Chem Lett, 15(5): 1397-9. [Abstract] [Full-text]
85. Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor.
    Cancer Gene Ther, 12(3): 313-20. [Abstract] [Full-text]
86. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
    J Pharmacol Exp Ther, 312(3): 978-88. [Abstract] [Full-text]
87. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers.
    J Cell Biol, 168(4): 633-42. [Abstract] [Full-text]
88. The risk of metachronous neoplasia in patients with serrated adenoma.
    Am J Clin Pathol, 123(3): 349-59. [Abstract] [Full-text]
89. Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study.
    Am J Epidemiol, 161(5): 462-71. [Abstract] [Full-text]
90. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol, 23(6): 1161-8. [Abstract] [Full-text]
91. PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas.
    Genomics, 85(3): 338-51. [Abstract] [Full-text]
92. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
    Nucl Med Biol, 32(2): 157-64. [Abstract] [Full-text]
93. Automated seed placement for colon segmentation in computed tomography colonography.
    Acad Radiol, 12(2): 182-90. [Abstract] [Full-text]
94. Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion: a follow-up study.
    Lancet, 365(9460): 681-2. [Abstract] [Full-text]
95. 3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation.
    Biochem Biophys Res Commun, 329(1): 40-5. [Abstract] [Full-text]
96. Free radical scavenging and apoptotic effects of Cordyceps sinensis fractionated by supercritical carbon dioxide.
    Food Chem Toxicol, 43(4): 543-52. [Abstract] [Full-text]
97. Epigenetics, mismatch repair genes and colorectal cancer.
    Ann R Coll Surg Engl, 87(1): 15-20. [Abstract] [Full-text]
98. CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.
    Neoplasia, 7(1): 85-90. [Abstract] [Full-text]
99. STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer.
    Neoplasia, 6(6): 813-20. [Abstract] [Full-text]
100. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer.
     Neoplasia, 6(6): 796-801. [Abstract] [Full-text]
101. Association between cyclooxygenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer.
     Histopathology, 46(3): 287-95. [Abstract] [Full-text]
102. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer?
     Colorectal Dis, 7(2): 176-81. [Abstract] [Full-text]
103. Targets and elective colorectal cancer: outcome and symptom delay at surgical resection.
     Colorectal Dis, 7(2): 169-71. [Abstract] [Full-text]
104. The role of colonoscopic endoanal ultrasound scanning (EUS) in selecting patients suitable for resection by transanal endoscopic microsurgery (TEM).
     Colorectal Dis, 7(2): 148-50. [Abstract] [Full-text]
105. An approach to haemorrhoids.
     Colorectal Dis, 7(2): 143-7. [Abstract] [Full-text]
106. Bipolar electrocoagulation vs conventional monopolar hot biopsy forceps in the endoscopic treatment of diminutive rectal adenomas.
     Colorectal Dis, 7(2): 138-42. [Abstract] [Full-text]
107. Postoperative morbidity and recurrence after local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery.
     Colorectal Dis, 7(2): 133-7. [Abstract] [Full-text]
108. Diet and colorectal cancer: implications for the obese and devotees of the Atkins diet.
     Colorectal Dis, 7(2): 128-32. [Abstract] [Full-text]
109. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
     Ann Oncol, 16(3): 425-9. [Abstract] [Full-text]
110. Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells.
     Cancer Chemother Pharmacol, 55(4): 369-78. [Abstract] [Full-text]
111. Prognostic scoring in colorectal cancer liver metastases: development and validation.
     Arch Surg, 140(2): 183-9. [Abstract] [Full-text]
112. Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy.
     Arch Surg, 140(2): 159-63; discussion 164. [Abstract] [Full-text]
113. Dynamics of antioxidants in patients with acute pancreatitis and in patients operated for colorectal cancer: a clinical study.
     Nutrition, 21(2): 118-24. [Abstract] [Full-text]
114. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate.
     Cancer Sci, 96(2): 69-76. [Abstract] [Full-text]
115. Perspectives in the treatment of colorectal cancer.
     Semin Oncol, 31(6): 14-8. [Abstract] [Full-text]
116. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
     Semin Oncol, 32(1): 120-7. [Abstract] [Full-text]
117. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
     Semin Oncol, 32(1): 113-9. [Abstract] [Full-text]
118. Combined modality treatment for rectal cancer.
     Semin Oncol, 32(1): 103-12. [Abstract] [Full-text]
119. Adjuvant therapy of colon cancer.
     Semin Oncol, 32(1): 95-102. [Abstract] [Full-text]
120. Liver-directed therapies in colorectal cancer.
     Semin Oncol, 32(1): 85-94. [Abstract] [Full-text]
121. Colorectal cancer vaccines: what we know and what we don't yet know.
     Semin Oncol, 32(1): 76-84. [Abstract] [Full-text]
122. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
     Semin Oncol, 32(1): 69-75. [Abstract] [Full-text]
123. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
     Semin Oncol, 32(1): 61-8. [Abstract] [Full-text]
124. The epidermal growth factor receptor as a target for colorectal cancer therapy.
     Semin Oncol, 32(1): 52-60. [Abstract] [Full-text]
125. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
     Semin Oncol, 32(1): 43-51. [Abstract] [Full-text]
126. Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).
     Semin Oncol, 32(1): 35-42. [Abstract] [Full-text]
127. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
     Semin Oncol, 32(1): 24-34. [Abstract] [Full-text]
128. Genetics of hereditary colorectal cancer.
     Semin Oncol, 32(1): 11-23. [Abstract] [Full-text]
129. Screening for colorectal cancer--now and the near future.
     Semin Oncol, 32(1): 3-10. [Abstract] [Full-text]
130. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells.
     Br J Cancer, 92(4): 729-35. [Abstract] [Full-text]
131. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
     Br J Cancer, 92(4): 722-8. [Abstract] [Full-text]
132. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
     Br J Cancer, 92(4): 655-61. [Abstract] [Full-text]
133. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer.
     Br J Cancer, 92(4): 651-4. [Abstract] [Full-text]
134. Chromosomal instability in flat adenomas and carcinomas of the colon.
     J Pathol, 205(4): 514-21. [Abstract] [Full-text]
135. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis.
     Br J Cancer, 92(4): 736-42. [Abstract] [Full-text]
136. Sporadic colorectal cancer--role of the commensal microbiota.
     FEMS Microbiol Lett, 244(1): 1-7. [Abstract] [Full-text]
137. Phytoestrogens and colorectal cancer prevention.
     Vitam Horm, 70: 169-98. [Abstract] [Full-text]
138. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations.
     Oncogene, 24(9): 1542-51. [Abstract] [Full-text]
139. Augmentation of differentiation and gap junction function by kaempferol in partially differentiated colon cancer cells.
     Carcinogenesis, 26(3): 665-71. [Abstract] [Full-text]
140. Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study.
     Int J Cancer, 114(5): 824-30. [Abstract] [Full-text]
141. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer.
     Carcinogenesis, 26(3): 587-95. [Abstract] [Full-text]
142. Meat intake, cooking-related mutagens and risk of colorectal adenoma in a sigmoidoscopy-based case-control study.
     Carcinogenesis, 26(3): 637-42. [Abstract] [Full-text]
143. The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.
     Carcinogenesis, 26(3): 579-85. [Abstract] [Full-text]
144. Colon polyps and cancer.
     Endoscopy, 37(3): 208-12. [Abstract] [Full-text]
145. Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy.
     Clin Endocrinol (Oxf), 62(3): 323-30. [Abstract] [Full-text]
146. Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor.
     Dig Surg, 21(5): 455-7. [Abstract] [Full-text]
147. A prospective audit of the complications of loop ileostomy construction and takedown.
     Dig Surg, 21(5): 440-6. [Abstract] [Full-text]
148. Expression of the hMLH1 and hMSH2 proteins in normal tissues: relationship to cancer predisposition in hereditary non-polyposis colon cancer.
     Virchows Arch, 446(2): 112-9. [Abstract] [Full-text]
149. Health care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial.
     J Clin Oncol, 23(7): 1548-54. [Abstract] [Full-text]
150. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
     J Clin Oncol, 23(7): 1365-9. [Abstract] [Full-text]
151. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
     Cancer Res, 65(4): 1335-42. [Abstract] [Full-text]
152. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.
     Cancer Res, 65(4): 1244-50. [Abstract] [Full-text]
153. Calcium, vitamin D, and apoptosis in the rectal epithelium.
     Cancer Epidemiol Biomarkers Prev, 14(2): 525-8. [Abstract] [Full-text]
154. Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer.
     Cancer Epidemiol Biomarkers Prev, 14(2): 437-43. [Abstract] [Full-text]
155. Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study.
     Cancer Epidemiol Biomarkers Prev, 14(2): 429-36. [Abstract] [Full-text]
156. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy.
     Cancer Epidemiol Biomarkers Prev, 14(2): 422-8. [Abstract] [Full-text]
157. Use of colonoscopy for colorectal cancer screening: evidence from the 2000 National Health Interview Survey.
     Cancer Epidemiol Biomarkers Prev, 14(2): 409-16. [Abstract] [Full-text]
158. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations.
     Radiology, 234(3): 785-92. [Abstract] [Full-text]
159. Case report: colonic manometry reveals abnormal propulsive behaviour after anterior resection of the rectum.
     Dig Liver Dis, 37(2): 124-8. [Abstract] [Full-text]
160. The I1307K APC mutation in a high-risk clinic setting: a follow-up study.
     Clin Genet, 67(4): 352-5. [Abstract] [Full-text]
161. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis.
     J Surg Oncol, 89(4): 211-7. [Abstract] [Full-text]
162. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer.
     J Surg Oncol, 89(4): 256-63; discussion 263-4. [Abstract] [Full-text]
163. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy.
     J Clin Oncol, 23(7): 1431-8. [Abstract] [Full-text]
164. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
     J Clin Oncol, 23(7): 1350-7. [Abstract] [Full-text]
165. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study.
     J Clin Oncol, 23(7): 1358-64. [Abstract] [Full-text]
166. Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma.
     J Biol Chem, 280(9): 8260-5. [Abstract] [Full-text]
167. Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocket.
     J Biol Chem, 280(9): 8180-7. [Abstract] [Full-text]
168. Radiation induces different changes in expression profiles of normal rectal tissue compared with rectal carcinoma.
     Virchows Arch, 446(2): 127-35. [Abstract] [Full-text]
169. Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells.
     Cell Biochem Funct, 23(2): 109-14. [Abstract] [Full-text]
170. DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells.
     J Biol Chem, 280(9): 7962-75. [Abstract] [Full-text]
171. Do benefits and barriers differ by stage of adoption for colorectal cancer screening?
     Health Educ Res, 20(2): 137-48. [Abstract] [Full-text]

© 2004-2008 Colorectal Cancer Research Today. All Rights Reserved.